Comorbidities Increase Mortality from Causes Other than Prostate Cancer, Study Reports

Comorbidities Increase Mortality from Causes Other than Prostate Cancer, Study Reports
The presence of one or more additional diseases (comorbidity) does not affect the risk of dying from prostate cancer, regardless of treatment type, a Swedish observational study reports. However, high comorbidity in prostate cancer patients is linked with increased mortality from other causes. The study, “Effect of Comorbidity on Prostate Cancer–Specific Mortality: A Prospective Observational Study,” was published in The Journal of Clinical Oncology. “Comorbidities are medical disorders that coexist with, but are distinct from, the primary diagnosis,” authors explained. They are usually associated with worsening health outcomes. While researchers have addressed comorbidity in prostate cancer patients, studies have reported conflicting results on its association with prostate cancer mortality. Researchers at the Queen Mary University of London, England, and the Karolinska Institute in Stockholm, Sweden, and colleagues investigated the effect of comorbidities on prostate cancer-specific mortality after accounting for patient and tumor characteristics. Treatment type was also taken into account in their analysis. These included radical prostatectomy (a surgical procedure for removing the prostate gland); radical radiotherapy (a non-surgical treatment using radiation); androgen deprivation therapy, and watchful waiting (a strategy that monitors prostate cancer that isn't causing any symptoms and avoids treatment unless it becomes symptomatic). The study included 118,543 prostate cancer patients
Subscribe or to access all post and page content.